Copyright
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Obstet Gynecol. Dec 6, 2024; 13(1): 100776
Published online Dec 6, 2024. doi: 10.5317/wjog.v13.i1.100776
Published online Dec 6, 2024. doi: 10.5317/wjog.v13.i1.100776
Serum fibroblast growth factor 21: Lack of association with gestational diabetes and pregnancy outcomes
Kuntharee Traisrisilp, Department of Obstetric and Gynecology, Maharaj Nakorn Chiang Mai Hospital, Chiang Mai University, Muang 50200, Chiang Mai, Thailand
Nattayaporn Apaijai, Siriporn Chattipakorn, Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Muang 50200, Chiang Mai, Thailand
Nipawan Waisayanand, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Muang 50200, Chiang Mai, Thailand
Siriporn Chattipakorn, Center of Excellence in Cardiac Electrophysiology Research, Chiang Mai University, Muang 50200, Chiang Mai, Thailand
Siriporn Chattipakorn, Department of Oral Biology and Diagnostic Sciences, Faculty of Dentistry, Chiang Mai University, Muang 50200, Chiang Mai, Thailand
Author contributions: Traisrisilp K acquired the data and drafted the manuscript; Traisrisilp K, Apaijai N, and Waisayanand N analyzed and interpreted the data; Traisrisilp K, Apaijai N, Waisayanand N, and Chattipakorn S conceived and designed the study; all of the authors read and approved the final version of the manuscript to be published.
Supported by The Faculty of Medicine Research Fund, Chiang Mai University, Thailand, No. 017/2564.
Institutional review board statement: The study was reviewed and approved by the Faculty of Medicine, Chiang Mai University, Institutional Review Board (Approval No. 328/2563).
Informed consent statement: All study participants provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors declare having no conflicts of interest.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE Statement–checklist of items, and the manuscript was prepared and revised according to the STROBE Statement–checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Kuntharee Traisrisilp, MSc, Doctor, Department of Obstetric and Gynecology, Maharaj Nakorn Chiang Mai Hospital, Chiang Mai University, 110 Intawaroros Road, Sriphoom District, Muang 50200, Chiang Mai, Thailand. kuntharee.t@cmu.ac.th
Received: August 26, 2024
Revised: October 29, 2024
Accepted: November 22, 2024
Published online: December 6, 2024
Processing time: 100 Days and 2.5 Hours
Revised: October 29, 2024
Accepted: November 22, 2024
Published online: December 6, 2024
Processing time: 100 Days and 2.5 Hours
Core Tip
Core Tip: Fibroblast growth factor 21 (FGF21) plays a role in glucose and lipid metabolism, prompting studies on its potential as a predictive marker for gestational diabetes mellitus (GDM). This investigation examined serum FGF21 levels in the early second trimester and their association with GDM. Although a trend toward higher FGF21 levels was noted in insulin-treated GDM patients, no significant association was found between FGF21 and GDM status nor pregnancy outcomes. Possible reasons include a small sample size, low body mass index among participants, and unexamined factors like physical activity. Further research is needed to clarify the role of FGF21 in GDM.